Bicara Therapeutics stock
BCAXNASDAQBicara Therapeutics Inc., HealthcareISIN US0554771032
32Score 32 out of 100, Weak
Price and trend
33 / 100
Price history
−32% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 52% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 27).
The price is 67% below its 52-week high. Largest decline in 2 years: 74% (July 2026 to November 2026).
Chart figures for advanced users
- SMA 50$17.10
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)27
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.93
- The lowest closing price of the last twelve months.
- Resistance$30.40
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bicara Therapeutics Inc. belongs to the Biotechnology industry (United States) and, with a market value of $671.17M, is number 220 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 32 out of 100 (Weak): rank 670 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $414.8M, financial debt $1.71M.Stability 69
Weaknesses
- Loss-makingLoss of $137.95M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$107.11M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 73% a year over the last 12 months.Stability 69
The score is held back by momentum and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 31 to 32.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 29 Mar 2027in 137 days
- Last reported
- 9 Nov 2026EPS reported −$1.04 (expected −$0.82)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.420.0%
- Revenue
- $0
- Earnings per share
- −$3.62−0.1%
- Revenue
- $0
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −11.2%No guidance change: the pivotal study is expected to be substantially enrolled by year end with a top-line interim analysis in mid-2027, operating expenses will keep rising.
“We anticipate increased spend within clinical operations to support our pivotal study, FORTIFI-HN01, particularly as we expect to be substantially enrolled by the end of this year to enable a top line interim analysis in the middle of 2027 as well as new investment in FORTIFI-FLEX, our alternative dosing study, which …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $4.22M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cohlhepp RyanSale
8 Sept 2026, President, COO & Interim CEO
- Shares
- 17,500
- Price
- $22.90
- Value
- $400,716
- Hyep IvanSale
10 Aug 2026, Chief Financial Officer
- Shares
- 12,500
- Price
- $27.97
- Value
- $349,591
- Mazumdar ClaireSale
10 Aug 2026, Chief Executive Officer
- Shares
- 10,000
- Price
- $27.98
- Value
- $279,750
Show 8 more
- Cohlhepp RyanSale
10 Aug 2026, President and COO
- Shares
- 18,750
- Price
- $27.98
- Value
- $524,533
- Mazumdar ClaireSale
10 Jul 2026, Chief Executive Officer
- Shares
- 10,000
- Price
- $28.42
- Value
- $284,198
- Cohlhepp RyanSale
9 Jul 2026, President and COO
- Shares
- 536
- Price
- $29.00
- Value
- $15,544
- Cohlhepp RyanSale
8 Jul 2026, President and COO
- Shares
- 28,214
- Price
- $28.98
- Value
- $817,585
- Hyep IvanSale
8 Jul 2026, Chief Financial Officer
- Shares
- 28,000
- Price
- $28.85
- Value
- $807,672
- Hyep IvanSale
21 May 2026, Chief Financial Officer
- Shares
- 9,200
- Price
- $20.42
- Value
- $187,883
- Mazumdar ClaireSale
18 May 2026, Chief Executive Officer
- Shares
- 15,000
- Price
- $20.04
- Value
- $300,579
- Cohlhepp RyanSale
15 May 2026, President and COO
- Shares
- 12,500
- Price
- $20.29
- Value
- $253,649
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bicara Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Nuvectis PharmaNVCT $722.17M48
- Immix BiopharmaIMMX $717.94M39
- Candel TherapeuticsCADL $705.5M36
- Zevra TherapeuticsZVRA $705.13M74
- ArriVent BioPharmaAVBP $698.78M30
- Cullinan TherapeuticsCGEM $697.55M35
- Ginkgo Bioworks HoldingsDNA $690.24M42
- Design TherapeuticsDSGN $689.67M37
ETFs that hold Bicara Therapeutics
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Show 5 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.00% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.00% | 0.43% | €2.48B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Sep 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.